Osteogenesis imperfecta

  title={Osteogenesis imperfecta},
  author={Frank Rauch and Francis H. Glorieux},
  journal={The Lancet},

Figures and Tables from this paper

Osteogenesis Imperfecta: Update on presentation and management
Cyclical intravenous pamidronate is now the standard of care for moderately to severely affected children with OI, given in combination with good orthopedic, physiotherapy and rehabilitation programs.
Osteogenesis imperfecta and therapeutics.
  • R. Morello
  • Medicine, Biology
    Matrix biology : journal of the International Society for Matrix Biology
  • 2018
Animal models of osteogenesis imperfecta and craniofacial development
The genetic mutations implicated in the eight different types of OI are reviewed, then, the craniofacial consequences of Oi mutations are summarized.
Treatment for OI is aimed at increasing bone strenght to prevent fracture, the surgical correction of deformity, minimizing pain and maximizing mobility and independent function.
Life style modifications by adaptive equipments, oral drugs and Intramedullary rod insertions, provide a significant degree of autonomy to OI patients to prevent fracture and maintain mobility.
Recent Advances in Osteogenesis Imperfecta
  • T. Cundy
  • Biology
    Calcified Tissue International
  • 2012
Bisphosphonates are widely used in patients with osteogenesis imperfecta, but some important questions about their optimal usage, their utility in children and adults with milder phenotypes, and their potential adverse effects are not yet resolved.
Infant with Osteogenesis Imperfecta and Panhypopituitarism: A Case Report
A Malay boy diagnosed with osteogenesis imperfecta at 3 months old was referred at the age of 2.2 years old for poor growth and severe failure to thrive and was stunted and wasted.
Osteogenesis imperfecta in adults: phenotypic characteristics and response to treatment in an Irish cohort
OI is debilitating disorder, but the course of the disease may be altered by treatment that increases BMD such as bisphosphonates and rhPTH, and both serial BMD and BTM aid in assessing response to intervention.
A rare case of osteogenesis imperfecta combined with complete tooth loss
This is the first report of an OI patient with a phenotype of complete tooth loss at a young age, and it is conceivable that the severity of the clinical phenotype may result from additional mutations in candidate genes responsible for abnormal dental phenotypes in this family.
Osteogenesis imperfecta type V
It is reported that while not all OI type V patients have hypertrophiccallus formation, all patients with hypertrophic callus formation are OItype V in the proper clinical context.


Osteogenesis imperfecta in childhood: treatment strategies.
Modern approach to children with osteogenesis imperfecta
Results allow for more efficacious corrective surgery using intramedullary rodding of the long bones and paravertegral instrumentation and justifies using bisphosphonates in order to reduce osteoclast mediated bone resorption.
Bisphosphonates in Children with Osteogenesis Imperfecta may Improve Bone Mineralization but not Bone Strength. Report of Two Patients
Two patients studied by bone dual energy X-ray absorptiometry (DEXA), and recently by peripheral quantitative computerized tomography (pQCT), provide quantitative assessments of volumetric bone density and of architectural variables such as bone diaphyseal area or cross-sectional moments of inertia.
Genetic heterogeneity in osteogenesis imperfecta.
An epidemiological and genetical study of osteogenesis imperfecta (OI) in Victoria, Australia confirmed that there are at least four distinct syndromes at present called OI. The largest group of
Osteogenesis Imperfecta Type VI: A Form of Brittle Bone Disease with a Mineralization Defect
It is concluded that type VI OI is a moderate to severe form of brittle bone disease with accumulation of osteoid due to a mineralization defect, in the absence of a disturbance of mineral metabolism.
Type V Osteogenesis Imperfecta: A New Form of Brittle Bone Disease
  • F. Glorieux, F. Rauch, N. Bishop
  • Medicine, Biology
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2000
OI type V is a new form of autosomal dominant OI, which does not appear to be associated with collagen type I mutations, and the genetic defect underlying this disease remains to be elucidated.
Severe osteogenesis imperfecta: new therapeutic options?
  • R. Smith
  • Biology, Medicine
    BMJ : British Medical Journal
  • 2001
Two new approaches using the aminobisphosphonates and stromal cell transplantation now deserve the critical attention in osteogenesis imperfecta.
Osteogenesis imperfecta: prospects for molecular therapeutics.
The present review will provide an update of OI clinical and molecular data and outline gene therapeutic approaches being tested on OI murine models for this disorder, especially mutation suppression by hammerhead ribozymes.
Pamidronate Treatment of Osteogenesis Imperfecta - Lack of Correlation Between Clinical Severity, Age at Onset of Treatment, Predicted Collagen Mutation and Treatment Response
Pamidronate treatment of severe forms of OI is an effective therapeutic modality to increase bone density, decrease fracture rate, increase mobility and improve quality of life, irrespective of the severity of the mutation or clinical phenotype.